Stevenson F K
Molecular Immunology Group, Southampton University Hospitals, UK.
Int J Clin Lab Res. 1992;22(2):84-9. doi: 10.1007/BF02591402.
Vaccination against tumor has always been an attractive idea for the treatment of patients bearing tumor. By harnessing the host's own immune response the attack on tumor cells would act on a continuing basis, with emerging tumor cells stimulating their own destruction. However, the approach has been hampered by our poor understanding of the nature of tumor antigens and of the pathways by which immune cells might operate against tumor growth. Recent developments in molecular biology and immunology are remedying this deficiency and bringing vaccination to the forefront of new approaches to treatment of a range of tumors. Results obtained in B-cell tumors, where the idiotypic immunoglobulin at the cell surface provides a well-defined tumor antigen, are already indicating exciting possibilities as well as delineating problems. There is considerable clinical evidence that patients have some intrinsic ability to control tumor growth and that certain tumors remain dormant for long periods. Attempts to understand and perhaps stimulate the mechanisms involved are being made through the use of biological modifiers and by manipulating potential effector cells in vitro. Ideally this approach, which may include non-specific and specific elements, could be combined with specific vaccination in order to combat the apparent ability of many tumor cells to evade host defences.
肿瘤疫苗接种一直是治疗肿瘤患者的一个颇具吸引力的想法。通过利用宿主自身的免疫反应,对肿瘤细胞的攻击将持续进行,新出现的肿瘤细胞会刺激自身被破坏。然而,由于我们对肿瘤抗原的性质以及免疫细胞对抗肿瘤生长可能采用的途径了解不足,这种方法受到了阻碍。分子生物学和免疫学的最新进展正在弥补这一缺陷,并使疫苗接种成为一系列肿瘤新治疗方法的前沿手段。在B细胞肿瘤中获得的结果已经显示出令人兴奋的可能性,同时也明确了问题,在B细胞肿瘤中,细胞表面的独特型免疫球蛋白提供了一个明确的肿瘤抗原。有大量临床证据表明,患者具有一定的内在控制肿瘤生长的能力,并且某些肿瘤会长期处于休眠状态。人们正在通过使用生物调节剂以及在体外操纵潜在的效应细胞来尝试理解并可能刺激其中涉及的机制。理想情况下,这种可能包括非特异性和特异性成分的方法可以与特异性疫苗接种相结合,以对抗许多肿瘤细胞逃避宿主防御的明显能力。